{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:13Z","timestamp":1790697913978,"version":"4.1.0"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To identify characteristics of patients with geographic atrophy (GA) who received pegcetacoplan or avacincaptad pegol and discontinued treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Two complementary retrospective cohort studies of a large, geographically and demographically diverse, deidentified database were performed. One analysis assessed baseline characteristics. Eyes with 12 months of data were included in a subsequent analysis of follow-up changes\/characteristics. Univariate and multivariate mixed-effects Cox proportional hazard and logistic regression models, respectively, were used to estimate the hazard ratio (HR) and odds ratio (OR) of attrition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 21\u2009914 eyes were identified for the baseline analysis, 14\u2009690 (67%) of which received pegcetacoplan and 7224 (33%) avacincaptad pegol. Mean (\u00b1SD) patient age was 82.1 \u00b1 7.85 years. Treatment retention declined between 0 and 12 months. Baseline predictors of attrition were age older than 90 years (HR, 1.26; 95% CI, 1.03-1.55;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .028), pegcetacoplan treatment (HR, 3.32; 95% CI, 2.92-3.76;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), treated (HR, 1.56; 95% CI, 1.40-1.75;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and untreated (HR, 1.41; 95% CI, 1.21-1.64;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) neovascular age-related macular degeneration (nAMD), visual acuity of less than 35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (HR, 1.45; 95% CI, 1.25-1.67;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), and subfoveal GA (HR, 1.15; 95% CI, 1.04-1.27;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .007). Poor baseline visual acuity remained significant in the adjusted 12-month analysis. Significant predictors included new nAMD (OR, 3.02; 95% CI, 2.35-3.89;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) and a loss of more than 5 ETDRS letters (OR, 1.36; 95% CI, 1.17-1.58;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). nAMD treatment intervals of more than 6 weeks (OR, 0.59; 95% CI, 0.39-0.90;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .014) and GA treatment intervals of 6 to 8 weeks (OR, 0.56; 95% CI, 0.43-0.74;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) contributed to decreased odds of attrition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Poor baseline vision and development of new nAMD are associated with patient attrition, and the combination of nAMD and GA and treatment burden challenges patient retention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/24741264261467244","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:52:36Z","timestamp":1785383556000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Examining Real-World Attrition Among Patients Undergoing Complement Inhibitor Intravitreal Therapy for Geographic Atrophy"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3281-5807","authenticated-orcid":false,"given":"Avi P.","family":"Bhavsar","sequence":"first","affiliation":[{"name":"Saint Louis University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Boucher","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusirini","family":"Fernando","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ishii","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2627-5203","authenticated-orcid":false,"given":"Deepak","family":"Sambhara","sequence":"additional","affiliation":[{"name":"Eye Clinic of Wisconsin, Wausau, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000001258"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26074"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.198"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.1407"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.015"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.05.050"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.02.007"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.110.223875"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6257(00)00140-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9587"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.03.021"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.165563"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10655"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09830"},{"issue":"123","key":"e_1_3_2_16_2","first-page":"337","article-title":"An emerging role of Alu RNA in geographic atrophy pathogenesis: the implication for novel therapeutic strategies","volume":"22","author":"Mao X","year":"2016","unstructured":"Mao X, Fang W, Liu Q. An emerging role of Alu RNA in geographic atrophy pathogenesis: the implication for novel therapeutic strategies. Discov Med. 2016;22(123):337-349.","journal-title":"Discov Med"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01520-9"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Khanani AM Patel SS Staurenghi G et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised double-masked phase 3 trial. Lancet (London England). 2023;402(10411):1449-1458. Comment in: Immunotherapy. 2024 Mar;16(4):205-221. doi: 10.2217\/imt-2023-0274. PMID: 38270081 [https:\/\/pubmed.ncbi.nlm.nih.gov\/38270081]. doi:https:\/\/dx.doi.org\/10.1016\/S0140-6736(23)01583-0","DOI":"10.1016\/S0140-6736(23)01583-0"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","unstructured":"Chakravarthy U Schwartz R Guymer RH et al. Visual function benefit after treatment with pegcetacoplan: microperimetry analysis from the phase 3 oaks trial. Am J Ophthalmol. 2025; 273:119-129. Erratum in: Am J Ophthalmol. 2025 May 29:S0002-9394(25)00244-2. doi: 10.1016\/j.ajo.2025.05.012. PMID: 40447477 [https:\/\/pubmed.ncbi.nlm.nih.gov\/40447477]. doi:https:\/\/dx.doi.org\/10.1016\/j.ajo.2025.02.012","DOI":"10.1016\/j.ajo.2025.05.012"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.023"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.05.011"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003796"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.11.032"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100421"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.3705"},{"key":"e_1_3_2_26_2","unstructured":"Posit t. RStudio: Integrated Development Environment for R. 2025. http:\/\/www.posit.co\/"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231220224"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20210330-03"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.01.057"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.06.023"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000538975"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Liao DS Grossi FV El Mehdi D et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127(2):186-195. Comment in: Ophthalmology. 2020 Feb;127(2):196-197. doi: 10.1016\/j.ophtha.2019.09.008 PMID: 31973832 [https:\/\/pubmed.ncbi.nlm.nih.gov\/31973832] Comment in: Immunotherapy. 2022 Sep;14(13):995-1006. doi: 10.2217\/imt-2022-0078 PMID: 35860926 [https:\/\/pubmed.ncbi.nlm.nih.gov\/35860926]. doi:https:\/\/dx.doi.org\/10.1016\/j.ophtha.2019.07.011","DOI":"10.1016\/j.ophtha.2019.07.011"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Patel SS Lally DR Hsu J et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023;37(17):3551-3557. Erratum in: Eye (Lond). 2023 Dec;37(17):3705. doi: 10.1038\/s41433-023-02548-2 PMID: 37237234 [https:\/\/pubmed.ncbi.nlm.nih.gov\/37237234]. doi:https:\/\/dx.doi.org\/10.1038\/s41433-023-02497-w","DOI":"10.1038\/s41433-023-02497-w"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.S341739"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.94.10.1788"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/21501319221082352"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.017"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.01.006"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.06.053"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00288-0"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.1.88"},{"key":"e_1_3_2_43_2","article-title":"When patients lose financial assistance, retinal disease management suffers","author":"Leveene S.","year":"2025","unstructured":"Leveene S. When patients lose financial assistance, retinal disease management suffers. Am Acad Ophthalmol. 2025.","journal-title":"Am Acad Ophthalmol"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35721"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.04.023"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261467244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261467244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261467244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:27Z","timestamp":1790695467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261467244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":44,"alternative-id":["10.1177\/24741264261467244"],"URL":"https:\/\/doi.org\/10.1177\/24741264261467244","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"24741264261467244"}}